𝐑𝐞𝐠𝐞𝐧𝐞𝐫𝐨𝐧 𝐀𝐜𝐪𝐮𝐢𝐫𝐞𝐬 𝐎𝐱𝐮𝐥𝐚𝐫 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐑𝐞𝐭𝐢𝐧𝐚𝐥 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬
👁 Regeneron Pharmaceuticals has acquired Oxular, a UK-based company specializing in ocular delivery technology for retinal disorders. Oxular's lead candidate, OXU-001, uses their proprietary Oxulumis microcatheter for targeted delivery of dexamethasone to the eye, potentially offering up to one year of effectiveness.
👨⚕️ This acquisition allows Regeneron to enhance treatment options for retinal disorders like diabetic macular edema (DME), improving patient care in ophthalmology.